Mandate

Vinge wins in the Swedish Supreme Court – Vinge acts as counsel in important case for the real estate sector

March 31, 2021 Dispute Resolution

The Swedish Supreme Court has delivered its judgment today in a case concerning the formal requirements in the Swedish Tenant-Owners Associations Act in connection with so-called preliminary agreements for newly produced tenant-owner properties.

The issue in the case related to how the statutory requirement relating to the “estimated date of the grant” should be construed. In its judgement, the Swedish Supreme Court stated that an estimated date for the grant can be specified as a time interval. The agreement in question specified a period of six months, which was thus deemed to fulfil the formal requirement according to the Swedish Tenant-Owners Associations Act. The Swedish Supreme Court’s judgement constitutes an important clarification for the real estate sector.

The successful tenant-owners’ association was advised by Vinge through advokat Cecilia Möller Norsted and advokat Philip Danielsson.

You can read the complete judgment here.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025